Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative disease characterized by progressive loss of memory and cognitive dysfunction. The primary pathological hallmarks of AD are senile plaques formed by deposition of amyloid β (Aβ) protein, intracellular neurofibrillary tangles resulting from hyperphosphorylation of microtubule-associated protein tau, and loss of neurons. At present, although the exact pathogenesis of AD is still unclear and there is a lack of effective treatment for AD in clinical practice, researchers have never stopped exploring the pathogenic mechanism of AD. In recent years, with the rise of the research of extracellular vesicles (EVs), people gradually realize that EVs also play important roles in neurodegenerative diseases. Exosomes, as a member of the small EVs, are regarded as carriers for information exchange and material transport between cells. Many cells of the central nervous system can release exosomes in both physiological and pathological conditions. Exosomes derived from damaged nerve cells can not only participate in Aβ production and oligomerization, but also disseminate the toxic proteins of Aβ and tau to neighboring neurons, thereby acting as “seeds” to amplify the toxic effects of misfolded proteins. Furthermore, exosomes may also be involved in the degradation and clearance process of Aβ. There is increasing evidence to suggest that exosomes play multiple roles in AD. Just like a double-edged sword, exosomes can participate in AD pathology in a direct or indirect way, causing neuronal loss, and can also participate in alleviating the pathological progression of AD. In this review, we summarize and discuss the current reported research findings on this double-edged role of exosomes in AD.
1. Introduction
Alzheimer’s disease (AD), also known as senile dementia, is one of the most prevalent central neurodegenerative diseases. AD mainly shows the gradual loss of self-care ability, progressive memory decline and behavioral cognitive impairment, accompanied by neuropsychiatric abnormalities, which seriously affect the quality of life of AD patients (). With the aging of the global population becoming increasingly prominent, the number of cases of AD is increasing year by year, which has become a major public health problem in front of us, and brought a heavy burden to individuals, society and families. Although the researchers have invested a great deal of financial resources and manpower to explore the pathogenesis of AD, it has not been fully elucidated, and to date, there is still no effective treatment available to stop the development of AD. Currently, with the rising and deepening of the research of extracellular vesicles (EVs), people have gradually realized that a kind of small EVs called exosomes to play a crucial role in AD pathogenic process ().
Exosomes are EVs with a phospholipid bilayer membrane structure. Exosomes can be released from most cell types and are widely present in biological fluids. Although exosomes containing specific cargoes are closely related to their parent cells of origin, they mainly include proteins, lipids, and nucleic acid molecules. Exosomes transport these cargoes from the donor cells to neighboring or more distant recipient cells, which can internalize exosomes from the extracellular space via several mechanisms including phagocytosis, pinocytosis, endocytosis or plasma membrane fusion (). In addition, exosomes are considered as a carrier tool that can move dynamically between cells and play an important role in material transfer and information exchange. Studies have shown that many cells in the central nervous system, including neurons, astrocytes, oligodendrocytes, microglia, and endothelial cells, can release exosomes and play both beneficial and pathogenic roles in physiological and pathological conditions (). It has been recognized that the two typical pathological features of AD are senile plaques formed by the deposition of extracellular amyloid β (Aβ) protein and intracellular neurofibrillary tangles formed by the hyperphosphorylation of microtubule-related protein tau (). There is increasing experimental evidence showing that exosomes play indispensable roles in the formation and dissemination of these two major pathological hallmarks (). More importantly, studies have found that exosomes can play a double-edged role in AD. On the one hand, exosomes derived from damaged nerve cells can transfer amyloid precursor protein (APP), γ/β-secretase, Aβ peptide, C-terminal APP and tau protein to adjacent healthy neurons to accelerate the death of peripheral neurons, thus leading to the spread of pathological features of AD (; ). On the other hand, exosomes also have a positive role in promoting Aβ clearance. For example, neuron-derived exosomes (NDEs) can transport Aβ to the lysosomes of microglia and degrade in the lysosomes (). In short, the roles of exosomes have been attracted much attention in AD. Many previous reviews have mainly illustrated the clinical value of exosomes in serum, plasma, urine or cerebrospinal fluid as a diagnostic tool in the early diagnosis of AD. However, the main focus of our study is to summarize the multiple roles of exosomes in the production, transport, dissemination and clearance of AD toxic proteins in order to provide new ideas for the pathogenesis, targeted therapy and early diagnosis of AD.
2. Biological characteristics of exosomes
Exosomes are small EVs with a diameter of 30-150nm. They can be widely isolated from a variety of body fluids, such as blood, cerebrospinal fluid, saliva, thoracic and abdominal fluids, urine, semen, breast milk, etc (; ). Exosome membranes are mainly composed of phospholipids and proteins. The surface of exosomes contains specific marker molecules (CD9, CD63, CD81, CD82, adhesion proteins, integrins, glycoproteins, etc.), and exosomes can pack a wide variety of cargoes, including but not limited to nucleic acids (microRNAs, mRNA, DNA, ribosomal RNA, long non-coding RNAs, etc.), proteins (Alix, tumor susceptibility gene 101 protein, heat shock proteins, lipid-associated proteins, cytoskeletal proteins, etc.) and lipids (lipid raft-associated lipids, ceramides, sphingolipids, phospholipids, glycerol phospholipids, etc.) (; Figure 1). Although the cargoes in exosomes are similar to some extent, they also have some cell specificity, which is related to the specific substances contained in the parent cells of their origins and the physiological or pathological conditions of exosome production. Additionally, exosome cargoes can change under different stimulus factors, and can be detected by proteomics technology, lipidomics technology, nucleic acid sequencing and digital PCR ().
FIGURE 1
In view of the biological characteristics of exosomes, the value of exosomes as biomarkers to distinguish healthy and disease states has attracted more and more attention. As a tool for disease diagnosis, exosomes have many unique advantages. Firstly, exosomes can be extracted from majority of body fluids in a convenient and non-invasive way, thus avoiding the damage to the organism caused by sampling. Secondly, exosomes are rich in cargoes, and their membrane structure can protect the cargoes from degradation by external factors, thereby maintaining their integrity and biological activity. Moreover, the exosome cargoes vary with the disease state and are closely related to the process of disease. Remarkably, exosomes can appear in peripheral blood by crossing the blood-brain barrier via bilayer lipid structure. Considering the prevalence of blood samples, researchers pay more attention to search for disease-specific biomarkers from blood exosomes. However, due to the widespread and complex sources of blood exosomes, the extracted total exosomes can not accurately reflect the disease status of the nervous system, and brain-derived exosomes (BDEs) need to be further isolated from blood exosomes.
3. Brain-derived exosomes
BDEs are a group of exosomes secreted by central nervous system cells, including neuron-derived exosomes (NDEs) and astrocyte-derived exosomes (ADEs). By detecting the changes of BDEs contents, the intrinsic pathological changes of brain can be indirectly reflected. This is not only to better explore the pathogenesis of exosomes in AD, but also to provide a minimally invasive method for the early diagnosis of AD, which is considered as a form of “liquid biopsy” (). A precipitate/immunoaffinity system has been developed at an earlier stage for the isolation of NDEs from peripheral blood. NDEs were first described in 2015. After extracting total plasma exosomes using ExoQuick exosome precipitation solution, NDEs are further isolated using antibodies against neuronal cell adhesion molecules (). Neuronal L1 cell adhesion molecule (L1CAM) or neural cell adhesion molecule (NCAM) can be used as a biomarker for isolating BDEs. This BDEs isolation technique has also been verified and used in other study (). In the same year, their experimental team took a similar approach with antibodies against glutamine aspartic acid transporters to enrich ADEs in peripheral blood (). The above innovative isolation methods of BDEs subsets have greatly triggered a research upsurge in the pathogenesis and biomarkers of central nervous system diseases. Subsequently, due to the development of experimental techniques, some other BDEs capture techniques have been gradually developed. For instance, a two-step immunocapture technique using immunomagnetic beads is established to isolate specific NCAM/amphiphysin 1 or NCAM/ATP-binding cassette transporter A1 (ABCA1) NDEs from total plasma exosomes (,). At present, most research strategies are to use L1CAM or NCAM antibody combined with magnetic beads to capture NDEs. Although earlier literatures have shown that L1CAM is an exosome surface marker molecule specifically derived from neurons (), there are some other studies have suggested that L1CAM is not only expressed in neurons, but also in other peripheral tissue cells (). Surprisingly, L1CAM has a soluble variant, which can exist in a free form in body fluids (). A more recently reported study indicates that L1CAM mainly exists in the form of free protein in cerebrospinal fluid and plasma, and it may not be an ideal biomarker of NDEs (). Thus, the extraction purity of NDEs or ADEs is crucial for the subsequent experimental results. This requires better isolation and purification techniques and further needs to discover higher specificity of BDEs marker molecules.
4. Exosomes: a double-edged sword in Alzheimer’s disease
Although the understanding of exosome function in AD has not been fully elucidated, with the deepening and extensive research, increasing evidence supports that exosomes play multiple roles in AD. Just like a double-edged sword, exosomes can not only participate in the pathological process of AD in a direct or indirect way, causing neuronal loss, but also help in alleviating the progression of AD pathology. Based on the current research literature, we speculate that exosomes may be involved in the pathogenesis of AD in several ways. One way is that exosomes involve in the formation, oligomerization, plaque formation and clearance of Aβ. Another way is that exosomes can act as constantly moving carriers to transport toxic cargoes (such as Aβ, tau, inflammatory molecules, etc.) or beneficial cargoes (such as enkephalins, insulin-degrading enzymes, etc.) in the brain at short or long distances. Its dissemination mechanism is similar to that of prions. Additionally, both neurons and glial cells can release and take up exosomes. As a carrier of cell-to-cell communication, exosomes can mediate the interregulation between neurons and glial cells, thus participating in the development process of AD (Figure 2).
FIGURE 2
4.1. The pathogenic role of exosomes in AD
4.1.1. Exosomes and Aβ
4.1.1.1. Exosomes participate in the APP metabolic process
Aβ is a product of the sequential cleavage of the transmembrane APP by β- and γ-secretase. Normally, intracellular Aβ can be degraded through the endosomal-lysosomal pathway. However, once the impairment of this pathway (especially the dysfunction of key molecules involved in the Aβ degradation process, such as metalloproteinase endothelin-converting enzyme), it can lead to the intracellular accumulation of Aβ, thereby making it easier for Aβ and APP metabolites to be encapsulated in exosomes and released into the extracellular space via exosomes (). Many earlier reports have described the presence of APP-associated proteins and their metabolites during Aβ production in exosomes of AD cell models and AD patients. Rajendran et al. first reported the existence of APP in exosomes, and the cleavage of β-secretase occurs in the early endosome. A minute fraction of Aβ can be secreted from the cells in association with exosomes and released from APP-transfected cells into the culture medium. Furthermore, they found that the brain slices of all AD patients show the enrichment of exosome marker Alix around small neuritic plaques, thus confirming the accumulation of exosomes around the amyloid plaques (). Subsequently, Vingtdeux et al. also observed the presence of APP-related metabolites APP-carboxyl-terminal fragments (CTFs) and amyloid intracellular domains (AICDs) in multivesicular bodies (MVBs) of differentiated neuroblastoma cells transfused with human APP. Their data showed that MVBs are essential organelles for APP metabolism, and all APP metabolites can be secreted into the extracellular space (). More importantly, several key members of the secretase family of proteases (β-site APP cleaving enzyme 1, presenilin 1, presenilin 2, and disintegrin and metalloprotease 10) can also be localized in exosomes (). APP-related metabolites in NDEs are also toxic and exhibit similar pathological features of AD in healthy neurons. Zheng et al. injected exosomes harvested from the conditioned medium of HEK293-APP Swe/Ind cells into the hippocampal dentate gyrus via a stereotactic approach. They found that exosomes containing pathogenic proteins (full-length APP and APP metabolites) showed higher neurotoxicity and could impair neurogenesis in the hippocampus (). In conclusion, considering the process of exosome formation, combined with the metabolic site and process of APP, it is not surprising that these endosome-associated protein products can be detected in neuronal exosomes under the pathological conditions of AD (Figure 2A).
In addition to the direct involvement of exosomes in APP metabolism through the above-mentioned ways, exosomes can also participate in indirect ways. A recent study reported a novel mechanism to regulate APP expression in different cells via the exosome-mediated miR-185-5p delivery. Exosomes isolated from AD mouse brains and APP-overexpressed N2a cell cultures significantly increased APP expression levels in recipient cells. Surprisingly, the effects of exosomes on APP expression in recipient cells are not mediated by the direct transferring of APP gene products. Instead, it is mediated by the reduction of the expression levels of miR-185-5p in exosomes (). This indirect regulation has increased the complexity of exosomes involved in APP metabolism, which still needs more evidence to confirm.
4.1.1.2. Exosomes promote Aβ aggregation and plaque formation
Emerging evidence suggests that exosomes can promote Aβ aggregation and then accelerate the formation of amyloid plaques. The correlation between exosomes and Aβ fibrosis is first reported in the study of Yuyama et al. In their study, they found that the assembly of Aβ is markedly accelerated when incubates with exosome portions prepared from the culture medium of PC12 cells treated with chloroquine and KCl. The formation of extracellular amyloid fibers is associated with GM1 gangliosides on exosomes, which is blocked by antibodies that recognize the GM1-Aβ complex (). Moreover, it was Yuyama and his colleagues who revealed that exosomes isolated from both N2a and primary neurons promote fibrillization of Aβ40 and Aβ42 with Aβ42 aggregation occurring more rapidly. Using cholera toxin B subunit blocking of ganglioside GM1 and endoglycoceramidase-treated glycosylysis in vitro cell experiments, they demonstrated that glycosphingolipids (GSLs) glycochains on the surface of exosomes play an important role in inducing the Aβ fibril formation (). GSLs are a group of glycochain membrane lipids that are localized on the outer layer of cells and exosomal membranes, and their glycans are exposed to the external environment. GSLs laterally traverse the cell membrane and form clusters at high densities, which monomeric Aβ is able to recognize and bind (). Many studies have documented that the rich lipid rafts in GSLs (including GM1 ganglioside) can bind to Aβ and promote its aggregation (; ). Exosomes, especially NDEs, enrich GSLs. Therefore, it is speculated that exosomes may indeed act as seeds for Aβ aggregation and plaque formation.
In addition to GSLs, cellular prion protein (PrP(C)) is also highly enriched in exosomes. PrP(C) is a glycosylphosphatidylinositol-anchored surface glycoprotein that is localized on the outer leaflet of the membranes of neurons and exosomes. Studies have proved that exosomes can also bind to Aβ via PrP(C), which has the highest binding affinity for dimeric, pentameric and oligomeric Aβ species, and accelerates the fibrosis of Aβ, thereby reducing the neurotoxic effects of oligomeric Aβ (). Taken together, these findings suggest that NDEs can capture Aβ via GSLs and PrP(C) in a single or synergistic manner, thus accelerating Aβ aggregation and amyloid plaque formation (Figure 2B).
4.1.1.3. Exosomes contribute to the spread of Aβ
On the one hand, NDEs, as described above, carry proteins associated with the Aβ generation pathway, such as APP, β-site APP cleaving enzyme 1, γ-secretase and their pyrolysis products β soluble APP, α soluble APP, CTFs and Aβ (). On the other hand, exosomes isolated from the brains of APP transgenic mice show higher levels of flAPP and APP CTFs than those of wild-type mice, suggesting that APP-related metabolites can accumulate in exosomes under the pathogenic conditions of AD, thus contributing to the spread of amyloid protein between cells (). The above two factors provide some theoretical basis for the pathological propagation of exosomes involved in AD. Accumulating evidence that Aβ can be transmitted in the brain from the source cells to the recipient cells by means of exosomes as vectors, in a way similar to prion diseases (Figure 2C). Research by Sinha et al. showed that exosomes can mediate the pathologic proliferation of Aβ between cells for the first time. NDEs have been demonstrated to mediate Aβ oligomers (oAβ) diffusion between neurons by co-localization of oAβ with exosomes in cells. Most importantly, exosomes carrying oAβ can be internalized in cultured neurons and spread their toxic contents to nearby cells. Blocking exosome formation, secretion, or uptake has been found to reduce oAβ diffusion and associated toxicity (). Besides, exosomes isolated from the cerebrospinal fluid and plasma of AD patients, or from the medium of neural cells expressing AD presenilin 1 mutations may mediate transcellular spread of pathogenic Aβ species, disrupt neuronal Ca2+ homeostasis, impair mitochondrial function, and induce neuronal apoptosis (). Another more convincing study is that Zheng et al. injected exosomes isolated from peripheral plasma into the hippocampus of AD mouse models in order to investigate the diffusion process of exosomes, and observed that exosomes can spread from the dentate gyrus to other regions of the hippocampus and cortex, and to the entire brain (). Another study showed that exosomes harvested from the conditioned medium of HEK293-APP Swe/Ind cells contain APP and are able to efficiently transfer APP to normal nerve cells, which also provides evidence for direct intercellular diffusion of amyloid proteins via exosomes ().
4.1.2. Exosomes and tau pathology
It is known that intracellular neurofibrillary tangles formed by hyperphosphorylated tau protein are one of the typical pathological features of AD, and the pathological proliferation of tau is also a hallmark of AD. Although the toxic effects of tau occur primarily inside the cell, tau can be released into the extracellular space as a “seed”. The tau “seeds” can be taken up by other healthy recipient cells and transferred from one cell to another (Figure 2C). Hence, tau pathology is spread through different regions of the brain in a manner similar to prions. This proliferative effect significantly promotes the pathological process of tau. However, in earlier times, investigators believe that tau is passively released into the extracellular space only through cell death, and then these membrane-free tau “seeds” spread to neighboring nerve cells (). On the contrary, in recent years, with the discovery of EVs, people gradually realize that exosomes can also serve as an important vehicle to actively secrete tau “seeds” into the extracellular environment. Recently, the role of exosomes in the spread of tau pathology has gradually become one of the hot issues concerned by many researchers.
Tau oligomers first pass through the endoplasmic reticulum and Golgi apparatus, then become part of vesicles and subsequently enter exosomes. Under physiological conditions, exosomes containing tau are degraded by lysosomes. However, once the lysosome is damaged, it contributes to tau accumulation in exosomes. Earlier studies have reported that some forms of tau exist in the EVs (), and these EVs isolated from neuronal culture can induce abnormal tau phosphorylation in the brain of wild-type mice, showing significant neurotoxic effects (). Moreover, another study revealed that most of the intracellular tau is full-length, while the bulk of the extracellular tau is free-floating, unaggregated and C-terminal truncated, lacking the microtubule binding regions necessary for aggregation. Only a small number of tau is encapsulated in exosomes (). These tau proteins packed in exosomes contain the microtubule binding regions and have the ability to aggregate. Furthermore, it has been confirmed that there are small amounts of full-length tau in neuronal exosomes (). In summary, the detailed mechanisms of tau encapsulated in exosomes still need further study.
Evidence from some studies illustrates that tau aggregates can spread and replicate in the brain in a prion-like manner via exosomes. Tau oligomers delivered by exosomes may act as “seeds”, and the uptake of pathological tau “seeds” leads to tau misfolding into a toxic conformation in recipient cells (). Exosomes isolated from the brains of tau transgenic rTg4510 mice carry a large number of tau “seeds”, thereby inducing endogenous tau aggregation in the recipient cells and increasing tau phosphorylation and oligomer formation. This evidence confirms that EVs are the carriers of tau pathology (; ). Many in vivo experiments have demonstrated that tau-containing neuronal exosomes from AD patients can induce the formation of neurofibrillary tangles (NFT) in rodents, exhibit tau neurotoxic effects, and thus reproduce the disease characteristics triggered by the original exosome contents. Winston et al. found that NDEs extracted from the plasma of patients with mild cognitive impairment and AD are able to seed p-tau pathology and induce AD-like neuropathology in the brains of normal mice (). In addition, another study has shown that neuronal exosomes derived from human tau have toxic effects on recipient mouse neurons in vivo and cause long-distance propagation of tau pathology and neurodegeneration (). A similar phenomenon has also been observed in the study of . Surprisingly, further research by Polanco et al. showed that a simple neuronal circuit model was built to observe the diffusion of exosomes in the interconnected neurons using a microfluidic culture system. The findings suggest that exosomes can spread the tau protein over long distances through a novel hijacking mechanism of endosomes, thereby increasing the pathogenic potential and radius of action of the exosomes (). In a recent study, to reveal how tau seeds contained within internalized exosomes exploit mechanisms of lysosomal degradation to escape the endosome and induce tau aggregation in the cytoplasm, their research team also found that the enzymatic activities of lysosomes can penetrate the exosomal and endosomal membranes, thereby promoting the entry of exosomal tau seeds into the cytoplasm and inducing its aggregation (). In earlier studies on the relationship between exosomes and tau, several studies described that the spread of tau pathology is achieved by the direct transmission of exosomes across synapses between interconnected neurons, and the depolarization of neurons faciliates the release of tau-containing exosomes (). Recent literatures have also reported that only exosomes and vesicle-free tau seeds are shown to propagate across synapses along neural networks (). Most of the exosomal tau released from AD synapses is C-terminal-truncated and oligomeric, and with seeding activity that is enhanced by Aβ (). These results also support the ideas that Aβ-induced pathology may directly or indirectly drive tau-mediated neurotoxicity and NFT formation ().
It is becoming increasingly clear that microglia may play a critical role in the interneuronal transmission of tau pathology promoted by exosomes. It has been shown that microglia can spread tauopathy by internalization and secretion of exosomes. Microglia propagates tau pathology via secretion of tau-containing exosomes. The depletion of microglia or the inhibition of exosome synthesis significantly reduces tau propagation in vitro and in vivo. Surprisingly, tau propagation mediated by microglia can occur not only through trans-synaptic transmission, but also in non-trans-synaptic pathways (). Most importantly, several reports have illustrated that some genes closely related to the risk of AD morbidity can interfere with the spread of tau pathology by influencing the production of exosomes in microglia. Bridging integrator 1 is a gene associated with late-onset AD. Overexpression of bridging integrator 1 promotes the release of tau-enriched EVs from microglia, and contributes to exacerbate tau pathology in P301S tau transgenic PS19 mice, thus promoting the spread of AD-related tau pathology (). Triggering receptor expressed on myeloid cells 2 (TREM2) is a transmembrane protein produced by microglia in the brain. Variations in TREM2 have been shown to increase the risk of late-onset AD (). It has been demonstrated that Trem2 deletion can enhance the transport, distribution and seeding of tau by microglial exosomes ().
4.1.3. Exosomes and inflammation
Increased research has focused on exosomes as important communication mediators between neurons and glial cells. Exosomes induce neuroinflammation by acting as inflammatory mediators via carrying inflammation-causing cargoes (). The accumulation of Aβ and hyperphosphorylation of tau have been shown to continuously activate microglia and astrocytes, and promote inflammatory responses (). Aβ or tau can be effectively encapsulated in exosomes, and activated glial cells or neuronal cells can release exosomes into the extracellular space, thus amplifying the neuroinflammatory effects caused by toxic proteins (). Additionally, microRNAs, as an important nucleic acid cargo in exosomes, have been found to be involved in the induction of neuroinflammation. It has been reported that NDEs containing miR-21-5p can be phagocytosed by microglia and induce microglia M1 polarization, which leads to increased release of neuroinflammatory factors, inhibition of neurite outgrowth, increased accumulation of P-tau, and increased the apoptosis of PC12 cells (). Another study from Wei et al. has shown that miR-182-5p delivered by plasma exosomes can target brain-derived neurotrophic factor (BDNF) and activate the nuclear transcription factor-κB pathway, thereby promoting sevoflurane-induced neuroinflammation and cognitive dysfunction in aged postoperative cognitive dysfunction rats (). In addition to enhancing and spreading inflammation in the extracellular microenvironment, exosomes can also play an anti-inflammatory role. Recent studies have reported the anti-inflammatory therapeutic value of exosomes due to their excellent properties, such as carrier transport, ease of modification and encapsulation of therapeutic agents. Related studies have also demonstrated that the activation of nucleotide-binding oligomerization domain-like receptor pyrin domain-containing 3 (NLRP3) inflammasome is closely associated with the occurrence of AD (). By blocking the assembly of NLRP3 inflammasome, the exosome-like nanoparticles from ginger rhizomes strongly inhibit the downstream pathways of NLRP3 inflammasome activation, including caspase1 autocleavage, interleukin 1β and interleukin 18 secretion, and pyroptotic cell death (). Under some specific conditions, exosomes released from microglia can also exert an anti-inflammatory role. For instance, the increased miR-124-3p in microglial exosomes promotes the anti-inflammatory M2 polarization of microglia, inhibits neuronal inflammation, and transfers into neurons to promote neurite outgrowth during traumatic brain injury (). Taken together, whether exosomes promote or inhibit the inflammatory response may be related to the different stimulants and the cell types that produce exosomes, and further research is needed to explore the potential mechanism.
4.2. The protective role of exosomes in AD
4.2.1. NDEs contribute to the Aβ clearance process mediated by glial cells
In contrast, while accumulated evidence has demonstrated that NDEs can be involved in the formation and spreading of the pathological features of AD, some studies have confirmed that NDEs also exert a protective role in the progression of AD. Therefore, NDEs play a dual role. Growing evidence indicates that NDEs and glial cell-derived exosomes may participate in Aβ clearance through independent or synergistic action and transfer neuroprotective substances between cells to alleviate the nervous system injury (Figure 2D). Earlier studies have shown that exosomes released from neuroblastoma N2a can capture and bind to Aβ via GSLs on their surface and be transported into microglia for degradation. Moreover, in vivo studies further provide evidence that the infusion of NDEs into the brains of APP mice can reduce Aβ levels and ameliorate Aβ-related pathologies (). The next year, further research demonstrated that neuronal exosomes, but not glial exosomes, have abundant GSLs and can capture Aβ. Infusion of neuronal exosomes into the brains of APP transgenic mice can reduce Aβ and amyloid deposition, and these findings highlight the role of neuronal exosomes capable of capturing Aβ as messengers for Aβ clearance (). All the above evidence have clearly demonstrated that intracerebral NDEs administration can improve the Aβ-related pathogenesis, which may provide a new direction for the treatment of AD. Furthermore, Yuyama et al. investigated that NDEs can drive the conformational changes of Aβ through GSLs on their surface. The changes in Aβ conformation can serve as seed on which other Aβ combines to form Aβ oligomers, and then form amyloid fibrinates. The Aβ-bound exosomes are endocytosed into endosomal-lysosomal system by microglia in a phosphatidylserine-dependent manner and promote the degradation of Aβ. Moreover, Yuyama et al. further demonstrated that the secretion of NDEs is modulated by the activity of sphingomyelin metabolic enzymes, including nSMase2 and sphingomyelin synthase 2. Inhibition of nSMase2 prevents exosome production, while inhibition of sphingomyelin synthase 2 promotes exosome release (). In the co-culture experiment of N2a cells transfected with human APP and microglia cells, inhibition of sphingomyelin synthase 2 activity to improve the secretion of neurons’ exosomes can enhance the uptake of Aβ by microglia cells, and significantly decrease the level of extracellular Aβ (). However, contrary to the results of this study, Dinkins et al. revealed that ADEs can also promote Aβ accumulation, but interfere with the uptake of Aβ by glial cells, thus promoting the formation of plaques in vivo. Inhibition of SMase2 activity by GW4869 or 5 × FAD mouse model targeted at nSMase2 gene deletion blocks exosome synthesis in vivo and in vitro, decreases the levels of Aβ1-42, alleviates amyloid plaque load in the brain of mice, and improves the cognitive deficits (, ). These results suggest that neurons and astrocyte-derived exosomes may differ in glial Aβ clearance, but the underlying mechanisms remain unclear.
4.2.2. Microglia-derived exosomes are involved in the remission of AD pathology
The evidence suggests that microglia and microglia-derived exosomes also play active roles in the mechanisms of Aβ clearance or tau pathologic protection. Earlier researches have shown that microglia exosomes contribute to the secretion of insulin degrading enzyme, which is an important enzyme for the extracellular degradation of Aβ (). According to a recent study, triggering receptor expressed on myeloid cells-2 (TREM2), expressed on the membrane of microglia exosomes, can mediate the secretion of exosomes. Free microglia exosomes can bind to Aβ through TREM2, releasing chemokines to alter the inflammatory levels surrounding Aβ and promote the recognition and phagocytosis of Aβ by microglia cells (). In addition to its roles in Aβ clearance, TREM2 can also affect tau pathology. Trem2 deletion, as previously described, can enhance tau trafficking, distribution, and pathological spread through microglia exosomes (; ). Conversely, upregulation of TREM2 in microglia inhibits the inflammatory response and ameliorates the pathological effects of activated microglia on neuronal tau hyperphosphorylation (). These evidence confirm that TREM2 can be involved in protecting tau pathology via microglia exosomes. P2X purinoceptor 7 (P2RX7) is an ATP-gated cationic channel, and its enrichment in microglia promotes exosome secretion. Administration of the P2RX7-specific inhibitor GSK1482160 to P301S tau mice significantly reduces the number of exosomes and accumulation of tau in the hippocampus, thereby improving working and contextual memory of model mice (). Inhibition of P2RX7 to down-regulate exosome expression can also be regarded as a novel pathway to improve tau pathology (Figure 2E).
4.2.3. The therapeutic role of stem cell-derived exosomes in AD
It is necessary to take into consideration that recent studies have focused on the therapeutic effects of exosomes in AD, which further demonstrates the beneficial effects of exosomes. In this review, the therapeutic values of exosomes from different sources in AD are summarized in Table 1. However, it should be noted that exosomes that play protective roles in these studies are mainly from healthy cells. At present, numerous reports have described that stem cell-derived exosomes may play a positive role in alleviating the pathological features of AD (Figure 2F). Research by Lee et al. showed that exosomes secreted by adipose-derived stem cells reduce β-amyloidosis and neuronal apoptosis in AD transgenic mouse models and enhance the axon growth in the brain of AD patients (). Further study indicates that mesenchymal stem cell (MSC)-derived exosomes can also significantly improve the pathological and cognitive deficits of AD (). Exosomes derived from bone-MSCs alleviate cognitive decline in AD-like mice by improving BDNF-associated neuropathology (). In addition, double transgenic APP/PS1 mice injected with bone-MSCs can activate the sphingosine kinase-1/sphingosine-1-phosphate signaling pathway to reduce Aβ deposition and promote cognitive function recovery in AD mice (). Exosomes isolated from human umbilical cord MSCs (hucMSCs) have been shown to have therapeutic effects in many inflammation-related diseases. Ding et al. observed that hucMSC-exosomes injection contributes to the removal of Aβ deposition, alleviates cognitive dysfunction in AD model mice, and regulates the activation of microglia cells, thus alleviating neuroinflammation (). Katsuda et al. also found that human adipose tissue-derived MSCs (ADSCs) secrete exosomes carrying the enzyme activity neprilysin (NEP). NEP is an enzyme that is important for the extracellular degradation of Aβ. The ADSCs-derived exosomes are transferred into N2a cells and reduced intracellular Aβ levels in N2a cells (, ). In addition to stem cells, some other cell-derived exosomes or bioengineered exosomes also play beneficial roles in AD. Pan et al. used human brain microvascular endothelial cells derived exosomes inheriting p-glycoprotein as an Aβ cleansing system to remove Aβ peptides from the brain by specific capture between p-glycoprotein and Aβ, which can facilitate the clearance of Aβ and effectively ameliorate the cognitive dysfunction of AD mice (). Moreover, M2 microglia-derived exosomes may also play a protective role in the pathogenesis of AD by improving PINK1/Parkin-mediated mitophagy (). Based on bioengineering technology, microglia-targeting exosomes and targeted drug delivery can be designed. Mannose-modified exosomes containing gemfibrozil can not only bind with Aβ, but also specifically target microglia, thereby promoting the entry of Aβ into microglia, activating lysosome activity by exosome gemfibrozil, and accelerating lysosome-mediated clearance of Aβ in microglia ().
TABLE 1
| Source of exosomes | Investigation model | Mechanism | References |
| ADSC | NSCs from the brains of TG2576 AD mice | Reducing Aβ42, Aβ40 levels, the cell apoptosis of AD neuronal cells and promoting the neurite growth. | |
| N2a cell line | Carrying enzymatically active neprilysin to decrease Aβ levels. | , | |
| MSC | Human neural cell culture model with FAD mutations and AD transgenic mice | Reducing Aβ expression, restoring the expression of neuronal memory/synaptic plasticity-related genes in the cell model and improving brain glucose metabolism and cognitive function in AD mice. | |
| BMSCs | A sporadic AD mouse model | Improving AD-like behaviors, inhibiting the hyperactivation of microglia and astrocytes, and improving BDNF-related neuropathology. | |
| APP/PS1 mice | Improving spatial learning and memory ability of APP/PS1 mice, enhancing the expression of SphK1 and S1P, inhibiting the levels of amyloid and promoting the expression of NeuN. | ||
| HucMSCs | AβPP/PS1 transgenic mice | Repairing cognitive disfunctions, clearing Aβ deposition, and alleviating neuroinflammation. | |
| HBMVECs | Aβ-induced AD mice model | Facilitating the cerebral clearance of Aβ and ameliorating cognitive dysfunction. | |
| M2 microglia | Neuronal HT-22 cells and APP/PS1 mice | Ameliorating PINK1/Parkin-mediated mitophagy | |
| MExo-Gem | BV2 cells and Aβ1–42-induced AD mice | Binding with Aβ and specifically target microglia, thus promoting lysosome-mediated clearance of Aβ and improving the learning and memory ability of AD mice. |
Protective roles of exosomes from different sources in AD.
AD, Alzheimer’s disease; Aβ, amyloid beta; ADSC, adipose-derived stem cells; NSCs, neuronal stem cells; MSC, mesenchymal stem cell; FAD, familial AD; BMSCs, bone-marrow mesenchymal stem cells, BDNF, brain-derived neurotrophic factor; SphK1, sphingosine kinase-1; S1P, sphingosine-1-phosphate; HucMSCs, human umbilical cord mesenchymal stem cells; HBMVECs, human brain microvascular endothelial cells, PINK1, PTEN-induced putative kinase1; MExo-Gem, mannose-modified exosomes laden with Gem.
5. Conclusions and future perspectives
In recent years, the research of exosomes is gradually becoming a new hotspot and receiving more and more attention. As a kind of widespread EVs, exosomes carry a variety of cargoes and are involved in the transport of substances, information transmission and cell-to-cell regulation, playing key roles in physiological and pathological conditions. Exosomes are also now known to play a critical role in the occurrence and development of AD. This review focuses on summarizing the “double-edged sword” role of exosomes in the pathogenesis of AD. In AD, exosomes can not only promote the production of pathological proteins, the formation of aggregates and the diffusion in the brain, but also enhance the inflammatory response to accelerate the pathological process. Meanwhile, exosomes can also alleviate the pathological process by promoting the clearance of Aβ or tau. In particular, given the complexity and multiplicity of exosome interactions between cells, more evidence is needed to reveal the roles of exosomes in AD in the future, especially imaging labeling techniques that provide dynamic real-time visualization of the pathogenesis of exosomes in cells or in animal models. In addition, exosomes may serve as potential biomarkers for AD due to their unique biological characteristics. Moreover, the regulation of exosome production or the modification of exosomes as biological carriers of specific molecules may become a new therapeutic measure for AD. However, the important factors limiting the basic research and clinical application of exosomes are the lack of more specific BDEs isolation and extraction technologies, the long time consumption and lack of unified and standardized extraction process, which requires extensive and in-depth researches in these aspects in the future. Last but not least, although it is a great interest to research the detrimental or beneficial roles of exosomes in the progression of AD, the current literature has generally avoided the potential mechanisms by which exosomes exert these varying functions. For example, is it specific surface proteins that prompt exosomes to spread Aβ or tau seeds between neuronal cells, rather than carrying them to microglia for degradation? In addition, the relationship between NDEs and Aβ shows multiple functions, including participating in the oligomerization of Aβ and playing a role in the clearance of Aβ via microglia cells. Whether there is a potential regulatory role in the seemingly contradictory relationship between them remains unknown. These questions may be a new direction to explore the roles of exosomes in AD in the future, which also requires further study by researchers.
Statements
Author contributions
TL designed, collected literatures, and wrote the manuscript. JL, WS, and SW collected some literatures. ZW and LW revised the article. All authors contributed to the article and approved the submitted version.
Funding
This study was supported by the Natural Science Foundation Program of Hubei Province (Grant number 2021CFB579 and 2022CFB181), the Special Fund of Union Hospital of Tongji Medical College, Huazhong University of Science and Technology (Grant No. 02.03.2018-130).
Acknowledgments
We are grateful to the editors and reviewers for giving valuable advice and important comments in the review.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AngioliniF.BelloniE.GiordanoM.CampioniM.FornerisF.ParonettoM. P.et al (2019). A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing.Elife8:e44305. 10.7554/eLife.44305
2
ArigaT.KobayashiK.HasegawaA.KisoM.IshidaH.MiyatakeT. (2001). Characterization of high-affinity binding between gangliosides and amyloid beta-protein.Arch. Biochem. Biophys.388225–230. 10.1006/abbi.2001.2304
3
AsaiH.IkezuS.TsunodaS.MedallaM.LuebkeJ.HaydarT.et al (2015). Depletion of microglia and inhibition of exosome synthesis halt tau propagation.Nat. Neurosci.181584–1593. 10.1038/nn.4132
4
AulstonB.LiuQ.ManteM.FlorioJ.RissmanR. A.YuanS. H. (2019). Extracellular Vesicles Isolated from Familial Alzheimer’s Disease Neuronal Cultures Induce Aberrant Tau Phosphorylation in the Wild-Type Mouse Brain.J. Alzheimer’s Dis.72575–585. 10.3233/JAD-190656
5
BakerS.PolancoJ. C.GötzJ. (2016). Extracellular vesicles containing P301L mutant tau accelerate pathological tau phosphorylation and oligomer formation but do not seed mature neurofibrillary tangles in ALZ17 mice.J. Alzheimer’s Dis.541207–1217. 10.3233/JAD-160371
6
Blurton-JonesM.LaferlaF. M. (2006). Pathways by which abeta facilitates tau pathology.Curr. Alzheimer Res.3437–448. 10.2174/156720506779025242
7
ChenX.ZhouY.YuJ. (2019). Exosome-like nanoparticles from ginger rhizomes inhibited NLRP3 inflammasome activation.Mol. Pharm.162690–2699. 10.1021/acs.molpharmaceut.9b00246
8
ChenY. A.LuC. H.KeC. C.ChiuS. J.JengF. S.ChangC. W.et al (2021). Mesenchymal stem cell-derived exosomes ameliorate Alzheimer’s disease pathology and improve cognitive deficits.Biomedicines9:594. 10.3390/biomedicines9060594
9
CrottiA.SaitH. R.McAvoyK. M.EstradaK.ErgunA.SzakS.et al (2019). BIN1 favors the spreading of tau via extracellular vesicles.Sci. Rep.9:9477. 10.1038/s41598-019-45676-0
10
DeLeoA. M.IkezuT. (2018). Extracellular vesicle biology in Alzheimer’s disease and related tauopathy.J. Neuroimmune Pharmacol.13292–308. 10.1007/s11481-017-9768-z
11
d’ErricoP.Meyer-LuehmannM. (2020). Mechanisms of pathogenic tau and Aβ protein spreading in Alzheimer’s disease.Front. Aging Neurosci.12:265. 10.3389/fnagi.2020.00265
12
DingL.YangX.XiaX.LiY.WangY.LiC.et al (2022). Exosomes mediate APP dysregulation via APP-miR-185-5p Axis.Front. Cell Dev. Biol.10:793388. 10.3389/fcell.2022.793388
13
DingM.ShenY.WangP.XieZ.XuS.ZhuZ.et al (2018). Exosomes isolated from human umbilical cord mesenchymal stem cells alleviate neuroinflammation and reduce amyloid-beta deposition by modulating microglial activation in Alzheimer’s disease.Neurochem. Res.432165–2177. 10.1007/s11064-018-2641-5
14
DinkinsM. B.DasguptaS.WangG.ZhuG.BieberichE. (2014). Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer’s disease.Neurobiol. Aging351792–1800. 10.1016/j.neurobiolaging.2014.02.012
15
DinkinsM. B.EnaskoJ.HernandezC.WangG.KongJ.HelwaI.et al (2016). Neutral sphingomyelinase-2 deficiency ameliorates Alzheimer’s disease pathology and improves cognition in the 5XFAD mouse.J. Neurosci.368653–8667. 10.1523/JNEUROSCI.1429-16.2016
16
DujardinS.BégardS.CaillierezR.LachaudC.DelattreL.CarrierS.et al (2014). Ectosomes: A new mechanism for non-exosomal secretion of tau protein.PLoS One9:e100760. 10.1371/journal.pone.0100760
17
EitanE.HutchisonE. R.MarosiK.ComottoJ.MustapicM.NigamS. M.et al (2016). Extracellular vesicle-associated Aβ mediates trans-neuronal bioenergetic and Ca2+-handling deficits in Alzheimer’s disease models.NPJ Aging Mech. Dis.216019–16019. 10.1038/npjamd.2016.19
18
FalkerC.HartmannA.GuettI.DohlerF.AltmeppenH.BetzelC.et al (2016). Exosomal cellular prion protein drives fibrillization of amyloid beta and counteracts amyloid beta-mediated neurotoxicity.J. Neurochem.13788–100. 10.1111/jnc.13514
19
FauréJ.LachenalG.CourtM.HirrlingerJ.Chatellard-CausseC.BlotB.et al (2006). Exosomes are released by cultured cortical neurones.Mol. Cell. Neurosci.31642–648. 10.1016/j.mcn.2005.12.003
20
FiandacaM. S.KapogiannisD.MapstoneM.BoxerA.EitanE.SchwartzJ. B.et al (2015). Identification of preclinical Alzheimer’s disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study.Alzheimers Dement.11600–607.e1. 10.1016/j.jalz.2014.06.008
21
FowlerC. D. (2019). NeuroEVs: Characterizing Extracellular Vesicles Generated in the Neural Domain.J. Neurosci.399262–9268. 10.1523/JNEUROSCI.0146-18.2019
22
GoetzlE. J.KapogiannisD.SchwartzJ. B.LobachI. V.GoetzlL.AbnerE. L.et al (2016a). Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer’s disease.FASEB J.304141–4148. 10.1096/fj.201600816R
23
GoetzlE. J.MustapicM.KapogiannisD.EitanE.LobachI. V.GoetzlL.et al (2016b). Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer’s disease.FASEB J.303853–3859. 10.1096/fj.201600756R
24
GomesP.TzouanouF.SkolarikiK.Vamvaka-IakovouA.Noguera-OrtizC.TsirtsakiK.et al (2022). Extracellular vesicles and Alzheimer’s disease in the novel era of Precision Medicine: Implications for disease progression, diagnosis and treatment.Exp. Neurol.358:114183. 10.1016/j.expneurol.2022.114183
25
Gómez-RamosA.Díaz-HernándezM.CuadrosR.HernándezF.AvilaJ. (2006). Extracellular tau is toxic to neuronal cells.FEBS Lett.5804842–4850. 10.1016/j.febslet.2006.07.078
26
GuixF. X.CorbettG. T.ChaD. J.MustapicM.LiuW.MengelD.et al (2018). Detection of aggregation-competent tau in neuron-derived extracellular vesicles.Int. J. Mol. Sci.19:663. 10.3390/ijms19030663
27
GuptaA.PulliamL. (2014). Exosomes as mediators of neuroinflammation.J. Neuroinflammation11:68. 10.1186/1742-2094-11-68
28
HaoY.SuC.LiuX.SuiH.ShiY.ZhaoL. (2022). Bioengineered microglia-targeted exosomes facilitate Aβ clearance via enhancing activity of microglial lysosome for promoting cognitive recovery in Alzheimer’s disease.Biomater. Adv.136:212770. 10.1016/j.bioadv.2022.212770
29
HayashiH.KimuraN.YamaguchiH.HasegawaK.YokosekiT.ShibataM.et al (2004). A seed for Alzheimer amyloid in the brain.J. Neurosci.244894–4902. 10.1523/JNEUROSCI.0861-04.2004
30
HuangS.GeX.YuJ.HanZ.YinZ.LiY.et al (2018). Increased miR-124-3p in microglial exosomes following traumatic brain injury inhibits neuronal inflammation and contributes to neurite outgrowth via their transfer into neurons.FASEB J.32512–528. 10.1096/fj.201700673R
31
HuangS.LiaoX.WuJ.ZhangX.LiY.XiangD.et al (2022). The Microglial membrane receptor TREM2 mediates exosome secretion to promote phagocytosis of amyloid-β by microglia.FEBS Lett.5961059–1071. 10.1002/1873-3468.14336
32
JacksonN. A.Guerrero-MuñozM. J.Castillo-CarranzaD. L. (2022). The prion-like transmission of tau oligomers via exosomes.Front. Aging Neurosci.14:974414. 10.3389/fnagi.2022.974414
33
JainN.UlrichJ. D. (2022). TREM2 and microglia exosomes: A potential highway for pathological tau.Mol. Neurodegener.17:73. 10.1186/s13024-022-00581-5
34
JiangT.ZhangY. D.GaoQ.OuZ.GongP. Y.ShiJ. Q.et al (2018). TREM2 ameliorates neuronal tau pathology through suppression of microglial inflammatory response.Inflammation41811–823. 10.1007/s10753-018-0735-5
35
KanmertD.CantlonA.MuratoreC. R.JinM.O’MalleyT. T.LeeG.et al (2015). C-terminally truncated forms of tau, but not full-length tau or its C-terminal fragments, are released from neurons independently of cell death.J. Neurosci.3510851–10865. 10.1523/JNEUROSCI.0387-15.2015
36
KanninenK. M.BisterN.KoistinahoJ.MalmT. (2016). Exosomes as new diagnostic tools in CNS diseases.Biochim. Biophys. Acta1862403–410. 10.1016/j.bbadis.2015.09.020
37
KatsudaT.OkiK.OchiyaT. (2015). Potential application of extracellular vesicles of human adipose tissue-derived mesenchymal stem cells in Alzheimer’s disease therapeutics.Methods Mol. Biol.1212171–181. 10.1007/7651_2014_98
38
KatsudaT.TsuchiyaR.KosakaN.YoshiokaY.TakagakiK.OkiK.et al (2013). Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes.Sci. Rep.3:1197. 10.1038/srep01197
39
LeeM.BanJ. J.YangS.ImW.KimM. (2018). The exosome of adipose-derived stem cells reduces β-amyloid pathology and apoptosis of neuronal cells derived from the transgenic mouse model of Alzheimer’s disease.Brain Res.169187–93. 10.1016/j.brainres.2018.03.034
40
LiT. R.WangX. N.ShengC.LiY. X.LiF. Z.SunY.et al (2019). Extracellular vesicles as an emerging tool for the early detection of Alzheimer’s disease.Mech. Ageing Dev.184:111175. 10.1016/j.mad.2019.111175
41
LiY.MengS.DiW.XiaM.DongL.ZhaoY.et al (2022a). Amyloid-β protein and MicroRNA-384 in NCAM-Labeled exosomes from peripheral blood are potential diagnostic markers for Alzheimer’s disease.CNS Neurosci. Ther.281093–1107. 10.1111/cns.13846
42
LiY.XiaM.MengS.WuD.LingS.ChenX.et al (2022b). MicroRNA-29c-3p in dual-labeled exosome is a potential diagnostic marker of subjective cognitive decline.Neurobiol. Dis.171:105800. 10.1016/j.nbd.2022.105800
43
LiangT.ZhangY.WuS.ChenQ.WangL. (2022). The role of NLRP3 inflammasome in Alzheimer’s disease and potential therapeutic targets.Front. Pharmacol.13:845185. 10.3389/fphar.2022.845185
44
LiuS.FanM.XuJ. X.YangL. J.QiC. C.XiaQ. R.et al (2022). Exosomes derived from bone-marrow mesenchymal stem cells alleviate cognitive decline in AD-like mice by improving BDNF-related neuropathology.J. Neuroinflammation19:35. 10.1186/s12974-022-02393-2
45
MiyoshiE.BilousovaT.MelnikM.FakhrutdinovD.PoonW. W.VintersH. V.et al (2021). Exosomal tau with seeding activity is released from Alzheimer’s disease synapses, and seeding potential is associated with amyloid beta.Lab. Investig.1011605–1617. 10.1038/s41374-021-00644-z
46
NormanM.Ter-OvanesyanD.TrieuW.LazarovitsR.KowalE.LeeJ. H.et al (2021). L1CAM is not associated with extracellular vesicles in human cerebrospinal fluid or plasma.Nat. Methods18631–634. 10.1038/s41592-021-01174-8
47
NovoaC.SalazarP.CisternasP.GherardelliC.Vera-SalazarR.ZolezziJ. M.et al (2022). Inflammation context in Alzheimer’s disease, a relationship intricate to define.Biol. Res.55:39. 10.1186/s40659-022-00404-3
48
Pacheco-QuintoJ.ClausenD.Pérez-GonzálezR.PengH.MeszarosA.EckmanC. B.et al (2019). Intracellular metalloprotease activity controls intraneuronal Aβ aggregation and limits secretion of Aβ via exosomes.FASEB J.333758–3771. 10.1096/fj.201801319R
49
PanJ.HeR.HuoQ.ShiY.ZhaoL. (2020). Brain microvascular endothelial cell derived exosomes potently ameliorate cognitive dysfunction by enhancing the clearance of Aβ through up-regulation of P-gp in mouse model of AD.Neurochem. Res.452161–2172. 10.1007/s11064-020-03076-1
50
PascualM.IbáñezF.GuerriC. (2020). Exosomes as mediators of neuron-glia communication in neuroinflammation.Neural. Regen. Res.15796–801. 10.4103/1673-5374.268893
51
Perez-GonzalezR.GauthierS. A.KumarA.LevyE. (2012). The exosome secretory pathway transports amyloid precursor protein carboxyl-terminal fragments from the cell into the brain extracellular space.J. Biol. Chem.28743108–43115. 10.1074/jbc.M112.404467
52
PolancoJ. C.GötzJ. (2022). Exosomal and vesicle-free tau seeds-propagation and convergence in endolysosomal permeabilization.FEBS J.2896891–6907. 10.1111/febs.16055
53
PolancoJ. C.HandG. R.BrinerA.LiC.GötzJ. (2021). Exosomes induce endolysosomal permeabilization as a gateway by which exosomal tau seeds escape into the cytosol.Acta Neuropathol.141235–256. 10.1007/s00401-020-02254-3
54
PolancoJ. C.LiC.DurisicN.SullivanR.GötzJ. (2018). Exosomes taken up by neurons hijack the endosomal pathway to spread to interconnected neurons.Acta Neuropathol. Commun.6:10. 10.1186/s40478-018-0514-4
55
PolancoJ. C.SciclunaB. J.HillA. F.GötzJ. (2016). Extracellular vesicles isolated from the brains of rTg4510 mice seed tau protein aggregation in a threshold-dependent manner.J. Biol. Chem.29112445–12466. 10.1074/jbc.M115.709485
56
RajendranL.HonshoM.ZahnT. R.KellerP.GeigerK. D.VerkadeP.et al (2006). Alzheimer’s disease beta-amyloid peptides are released in association with exosomes.Proc. Natl. Acad. Sci. U.S.A.10311172–11177. 10.1073/pnas.0603838103
57
ReillyP.WinstonC. N.BaronK. R.TrejoM.RockensteinE. M.AkersJ. C.et al (2017). Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation.Neurobiol. Dis.106222–234. 10.1016/j.nbd.2017.06.005
58
RuanZ.DelpechJ. C.Venkatesan KalavaiS.Van EnooA. A.HuJ.IkezuS.et al (2020). P2RX7 inhibitor suppresses exosome secretion and disease phenotype in P301S tau transgenic mice.Mol. Neurodegener.15:47. 10.1186/s13024-020-00396-2
59
Sardar SinhaM.Ansell-SchultzA.CivitelliL.HildesjöC.LarssonM.LannfeltL.et al (2018). Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers.Acta Neuropathol.13641–56. 10.1007/s00401-018-1868-1
60
SharplesR. A.VellaL. J.NisbetR. M.NaylorR.PerezK.BarnhamK. J.et al (2008). Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes.FASEB J.221469–1478. 10.1096/fj.07-9357com
61
SiZ. Z.ZouC. J.MeiX.LiX. F.LuoH.ShenY.et al (2023). Targeting neuroinflammation in Alzheimer’s disease: From mechanisms to clinical applications.Neural. Regen. Res.18708–715. 10.4103/1673-5374.353484
62
SolimanH. M.GhonaimG. A.GharibS. M.ChopraH.FaragA. K.HassaninM. H.et al (2021). Exosomes in Alzheimer’s disease: From being pathological players to potential diagnostics and therapeutics.Int. J. Mol. Sci.22:10794. 10.3390/ijms221910794
63
SongZ.XuY.DengW.ZhangL.ZhuH.YuP.et al (2020). Brain derived exosomes are a double-edged sword in Alzheimer’s disease.Front. Mol. Neurosci.13:79. 10.3389/fnmol.2020.00079
64
TamboliI. Y.BarthE.ChristianL.SiepmannM.KumarS.SinghS.et al (2010). Statins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion.J. Biol. Chem.28537405–37414. 10.1074/jbc.M110.149468
65
UllandT. K.ColonnaM. (2018). TREM2 - a key player in microglial biology and Alzheimer disease.Nat. Rev. Neurol.14667–675.
66
VingtdeuxV.HamdaneM.LoyensA.GeléP.DrobeckH.BégardS.et al (2007). Alkalizing drugs induce accumulation of amyloid precursor protein by-products in luminal vesicles of multivesicular bodies.J. Biol. Chem.28218197–18205. 10.1074/jbc.M609475200
67
WangX.YangG. (2021). Bone marrow mesenchymal stem cells-derived exosomes reduce Aβ deposition and improve cognitive function recovery in mice with Alzheimer’s disease by activating sphingosine kinase/sphingosine-1-phosphate signaling pathway.Cell Biol. Int.45775–784. 10.1002/cbin.11522
68
WangY.BalajiV.KaniyappanS.KrügerL.IrsenS.TepperK.et al (2017). The release and trans-synaptic transmission of Tau via exosomes.Mol. Neurodegener.12:5. 10.1186/s13024-016-0143-y
69
WeiF. S.RaoM. W.HuangY. L.ChenS. B.WuY. Q.YangL. (2022). miR-182-5p delivered by plasma exosomes promotes sevoflurane-induced neuroinflammation and cognitive dysfunction in aged rats with postoperative cognitive dysfunction by targeting brain-derived neurotrophic factor and activating NF-κB pathway.Neurotox. Res.401902–1912. 10.1007/s12640-022-00597-1
70
WengS.LaiQ. L.WangJ.ZhuangL.ChengL.MoY.et al (2022). The role of exosomes as mediators of neuroinflammation in the pathogenesis and treatment of Alzheimer’s disease.Front. Aging Neurosci.14:899944. 10.3389/fnagi.2022.899944
71
WinstonC. N.AulstonB.RockensteinE. M.AdameA.PrikhodkoO.DaveK. N.et al (2019). Neuronal exosome-derived human tau is toxic to recipient mouse neurons in vivo.J. Alzheimer’s Dis.67541–553. 10.3233/JAD-180776
72
WinstonC. N.GoetzlE. J.AkersJ. C.CarterB. S.RockensteinE. M.GalaskoD.et al (2016). Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile.Alzheimers Dement.363–72. 10.1016/j.dadm.2016.04.001
73
YinZ.HanZ.HuT.ZhangS.GeX.HuangS.et al (2020). Neuron-derived exosomes with high miR-21-5p expression promoted polarization of M1 microglia in culture.Brain Behav. Immun.83270–282. 10.1016/j.bbi.2019.11.004
74
YuyamaK.IgarashiY. (2022). Linking glycosphingolipids to Alzheimer’s amyloid-ß: Extracellular vesicles and functional plant materials.Glycoconj. J.39613–618. 10.1007/s10719-022-10066-8
75
YuyamaK.SunH.MitsutakeS.IgarashiY. (2012). Sphingolipid-modulated exosome secretion promotes clearance of amyloid-β by microglia.J. Biol. Chem.28710977–10989. 10.1074/jbc.M111.324616
76
YuyamaK.SunH.SakaiS.MitsutakeS.OkadaM.TaharaH.et al (2014). Decreased amyloid-β pathologies by intracerebral loading of glycosphingolipid-enriched exosomes in Alzheimer model mice.J. Biol. Chem.28924488–24498. 10.1074/jbc.M114.577213
77
YuyamaK.SunH.UsukiS.SakaiS.HanamatsuH.MiokaT.et al (2015). A potential function for neuronal exosomes: Sequestering intracerebral amyloid-β peptide.FEBS Lett.58984–88. 10.1016/j.febslet.2014.11.027
78
YuyamaK.YamamotoN.YanagisawaK. (2008). Accelerated release of exosome-associated GM1 ganglioside (GM1) by endocytic pathway abnormality: Another putative pathway for GM1-induced amyloid fibril formation.J. Neurochem.105217–224. 10.1111/j.1471-4159.2007.05128.x
79
ZhangT.MaS.LvJ.WangX.AfewerkyH. K.LiH.et al (2021). The emerging role of exosomes in Alzheimer’s disease.Ageing Res. Rev.68:101321. 10.1016/j.arr.2021.101321
80
ZhengT.PuJ.ChenY.GuoZ.PanH.ZhangL.et al (2017a). Exosomes secreted from HEK293-APP Swe/Ind cells impair the hippocampal neurogenesis.Neurotox. Res.3282–93. 10.1007/s12640-017-9713-1
81
ZhengT.PuJ.ChenY.MaoY.GuoZ.PanH.et al (2017b). Plasma exosomes spread and cluster around β-amyloid plaques in an animal model of Alzheimer’s disease.Front. Aging Neurosci.9:12. 10.3389/fnagi.2017.00012
82
ZhengT.WuX.WeiX.WangM.ZhangB. (2018). The release and transmission of amyloid precursor protein via exosomes.Neurochem. Int.11418–25. 10.1016/j.neuint.2017.12.009
83
ZhuB.LiuY.HwangS.ArchuletaK.HuangH.CamposA.et al (2022). Trem2 deletion enhances tau dispersion and pathology through microglia exosomes.Mol. Neurodegener.17:58. 10.1186/s13024-022-00562-8
Summary
Keywords
Alzheimer’s disease, exosomes, pathogenesis, amyloid β, tau
Citation
Liang T, Wu Z, Li J, Wu S, Shi W and Wang L (2023) The emerging double-edged sword role of exosomes in Alzheimer’s disease. Front. Aging Neurosci. 15:1209115. doi: 10.3389/fnagi.2023.1209115
Received
20 April 2023
Accepted
31 May 2023
Published
16 June 2023
Volume
15 - 2023
Edited by
Allison B. Reiss, New York University, United States
Reviewed by
Siranjeevi Nagaraj, Université Libre de Bruxelles, Belgium; Ming Cai, Shanghai University of Medicine & Health Sciences, China
Updates
Copyright
© 2023 Liang, Wu, Li, Wu, Shi and Wang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lin Wang, lin_wang@hust.edu.cn
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.